MDD is a highly drug-treated condition that utilizes an array of drug classes, including, but not limited to, SSRI , SNRI s, and—as adjunctive therapies—atypical antipsychotics. Even though the MDD drug market is highly entrenched with generic therapies, MDD patients’ heterogeneous response to antidepressants and/or atypical antipsychotics afford branded drugs (, Trintellix [Lundbeck/Takeda], Rexulti [Otsuka Pharmaceuticals/Lundbeck]) the opportunity to be introduced into the treatment paradigm, often as later-line therapies. Given MDD ’s highly crowded and competitive landscape, it is valuable for drug marketers and developers to understand how MDD patients are being treated using claims data.
What patient share do key therapies and brands garner by line of therapy in newly diagnosed MDD patients? What are the quarterly trends in prescribing among recently-treated and new diagnosed MDD patients?
How have antidepressants and atypical antipsychotics been integrated into the treatment algorithm?
What proportion of MDD patients receive drug therapy within one year of diagnosis, and how quickly?
What percentage of patients progress to later lines of therapy within one year of diagnosis?
What percentage of MDD patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
What are the product-level compliance and persistency rates among drug-treated patients with MDD ?
Treatment Algorithms: Claims Data Analysis (Truven) provides detailed analysis of brand usage across different lines of therapy using real-world data patient-level claims data so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.